Results 61 to 70 of about 54,427 (226)

hMENA11a contributes to HER3-mediated resistance to PI3K inhibitors in HER2-overexpressing breast cancer cells. [PDF]

, 2015
Human Mena (hMENA), an actin regulatory protein of the ENA/VASP family, cooperates with ErbB receptor family signaling in breast cancer. It is overexpressed in high-risk preneoplastic lesions and in primary breast tumors where it correlates with HER2 ...
Circo, R, De Maria, R, Di Benedetto, A, Di Modugno, F, Matteoni, S, Melchionna, R, Mottolese, M, Nisticò, P. 1., Palermo, Belinda, Soddu, S, Spada, Sheila, Trono, P   +11 more
core   +2 more sources

Clinical-pathological features of an occult mixed mucinous male breast cancer. a case report [PDF]

, 2017
Mucinous carcinoma of the male breast is an uncommon malignant breast neoplasm and its diagnoses remain difficult. It is probably due to such a low rate of breast cancer cases that men tend to be diagnosed at an older age than women and with a later ...
Bonifacino, Adriana, Carico, Elisabetta, Giarnieri, Enrico, Giovagnoli, Maria Rosaria, Lamberti, Ilaria, Mancini, Rita, Scarpino, Stefania, Villani, Sandra   +7 more
core   +1 more source

Neuregulin promotes incomplete autophagy of prostate cancer cells that is independent of mTOR pathway inhibition. [PDF]

PLoS ONE, 2012
Growth factors activating the ErbB receptors have been described in prostate tumors. The androgen dependent prostate cancer cell line, LNCaP, expresses the ErbB-1, ErbB-2 and ErbB-3 receptor tyrosine kinases.
Eran Schmukler, Ben Shai, Marcelo Ehrlich, Ronit Pinkas-Kramarski   +3 more
doaj   +1 more source

Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma [PDF]

, 2015
Patients with metastatic melanoma bearing V600 mutations in BRAF oncogene clinically benefit from the treatment with BRAF inhibitors alone or in combination with MEK inhibitors.
Ascierto, Paolo Antonio, Aurisicchio, Luigi, Belleudi, Francesca, Camerlingo, Rosa, Ciliberto, Gennaro, Coluccia, Pierpaolo, DE VITIS, Claudia, DI NAPOLI, Arianna, Fattore, Luigi, Malpicci, Debora, Mancini, Rita, Marra, Emanuele, Noto, Alessia, Pisanu, Maria Elena, Ribas, Antoni, Roscilli, Giuseppe, Torrisi, Maria Rosaria   +16 more
core   +4 more sources

Recurrent cancer‐associated ERBB4 mutations are transforming and confer resistance to targeted therapies

Molecular Oncology, EarlyView.
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala, Sini Ahonen, Sara Peltola, Aura Tuohisto‐Kokko, Olaya Esparta, Peppi Suominen, Anne Jokilammi, Iman Farahani, Deepankar Chakroborty, Nikol Dibus, Steffen Boettcher, Tomi T. Airenne, Mark S. Johnson, Lisa D. Eli, Klaus Elenius, Kari J. Kurppa   +15 more
wiley   +1 more source

ErbB Receptors and ErbB Targeted Therapies in Endometrial Cancer

Journal of Cancer Therapy, 2014
The Epidermal Growth Factor system is present in human organs and plays an important role in cell proliferation, differentiation and apoptosis during embryogenesis and postnatal development. It has four receptors (EGFR, ErbB-2, ErbB-3 and ErbB-4) and numerous ligands.
Georgios Androutsopoulos, Georgios Michail, Georgios Adonakis, Georgios Decavalas   +3 more
openaire   +2 more sources

HER2 testing in breast cancer: Opportunities and challenges [PDF]

, 2006
Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Annette Lebeau, Arnould L, Baselga J, Bast, Bilous M, Carter P, Cho HS, Clynes RA, Cobleigh MA, Connor CS, Crowder RJ, Dandachi N, De Laurentiis M, Di Leo A, Di Loreto C, Goldhirsch A, Gschwind A, Hancock MC, Hanna W, Harari D, Hortobagyi GN, Hudziak RM, Jacobs TW, Kobayashi M, Lebeau A, Lohrisch C, Mass R, Mass R, Molina MA, Mueller-Holzner E, Nagata Y, Osborne CK, Paik S, Piccart MJ, Piccart-Gebhart MJ, Pietras RJ, Pinto AE, Revillion F, Romond EP, Ross JS, Seidman AD, Sliwkowski MX, Tanner M, Taucher S, Yakes FM, Yarden Y   +45 more
core   +1 more source

Network divergence analysis identifies adaptive gene modules and two orthogonal vulnerability axes in pancreatic cancer

Molecular Oncology, EarlyView.
Tumors contain diverse cellular states whose behavior is shaped by context‐dependent gene coordination. By comparing gene–gene relationships across biological contexts, we identify adaptive transcriptional modules that reorganize into distinct vulnerability axes.
Brian Nelson, Lyanne Delgado‐Coka, Natalia Marchenko, Luisa F. Escobar‐Hoyos, Kenneth R. Shroyer, Alisa Yurovsky, Trey Ideker, Gábor Balázsi, Thomas MacCarthy, Scott Powers   +9 more
wiley   +1 more source

Long-term response to second-line afatinib treatment for advanced squamous cell carcinoma non-small cell lung cancer: a rare case report

Journal of International Medical Research, 2020
The ErbB family is composed of four cell membrane receptors: ErbB-1 (epidermal growth factor receptor or human epidermal growth factor receptor [HER]1), ErbB-2 (HER2), ErbB-3 (HER3), and ErbB-4 (HER4).
Mengyao Sun, Ye Guo, Xu Wang, Chao Sun, Jiangbo Shao, Yinghui Xu, Shi Qiu, Kewei Ma   +7 more
doaj   +1 more source

Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors

Cell Reports Medicine, 2021
Summary: Utilizing T cells expressing chimeric antigen receptors (CARs) to identify and attack solid tumors has proven challenging, in large part because of the lack of tumor-specific targets to direct CAR binding. Tumor selectivity is crucial because on-
Paris Kosti, James W. Opzoomer, Karen I. Larios-Martinez, Rhonda Henley-Smith, Cheryl L. Scudamore, Mary Okesola, Mustafa Y.M. Taher, David M. Davies, Tamara Muliaditan, Daniel Larcombe-Young, Natalie Woodman, Cheryl E. Gillett, Selvam Thavaraj, John Maher, James N. Arnold   +14 more
doaj   +1 more source